Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women

This study has been terminated.

Sponsored by:	National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by:	National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:	NCT00000809

Purpose

The purpose of this study is to test the safety and effectiveness of two different formulations of an HIV vaccine in infants born to HIV-infected women.

Condition	Intervention	Phase
HIV Infections HIV Seronegativity	Biological: Aluminum hydroxide Biological: QS-21 Biological: MN rsgp120/HIV-1	Phase I

MedlinePlus related topics: AIDS

Drug Information available for: Aluminum hydroxide Algeldrate QS 21 Aluminum Alum, potassium Aluminum sulfate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Prevention, Dose Comparison
Official Title:	A Phase I Trial of the Safety and Immunogenicity of MN rsgp120/HIV-1 With the Adjuvants QS-21 and Alum Compared to MN rsgp120/HIV-1 and QS-21 in Infants Born to HIV-Infected Women

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Estimated Enrollment:

Eligibility

Ages Eligible for Study:	up to 3 Days
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria

Infants may be eligible for this study if they:

Are 1 to 3 days old.

Contacts and Locations

No Contacts or Locations Provided

More Information

Study ID Numbers:	ACTG 279
Study First Received:	November 2, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000809
Health Authority:	United States: Federal Government

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):

HIV Preventive Vaccine
HIV Therapeutic Vaccine

Study placed in the following topic categories:

Virus Diseases
Sexually Transmitted Diseases, Viral
Aluminum sulfate
HIV Infections
Sexually Transmitted Diseases

Acquired Immunodeficiency Syndrome
QS 21
Retroviridae Infections
Immunologic Deficiency Syndromes
Aluminum Hydroxide

Additional relevant MeSH terms:

RNA Virus Infections
Slow Virus Diseases
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Immune System Diseases
Physiological Effects of Drugs

Adjuvants, Immunologic
Lentivirus Infections
Antacids
Infection
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 15, 2009